Milligram for milligram, oxycodone is roughly 50 percent stronger than hydrocodone. In standard conversion tables used by pharmacists and pain specialists, 10 mg of hydrocodone equals about 15 mg of morphine, while 10 mg of oxycodone equals about 15 mg of morphine as well, but that only works because prescribers already account for the potency gap by adjusting the dose. The real-world picture, though, is more interesting than a simple potency ranking suggests, because when doses are adjusted to be equivalent, clinical trials have struggled to find a meaningful difference in pain relief between the two drugs.
What “Stronger” Actually Means in Pharmacology
When researchers and prescribers compare opioids, they use a standardized metric called morphine milligram equivalents. Morphine gets a conversion factor of 1. Hydrocodone also gets a factor of 1, meaning it’s treated as roughly equal to morphine on a milligram basis. Oxycodone gets a factor of 1.5, meaning each milligram of oxycodone is considered about one and a half times as potent as the same weight of hydrocodone or morphine.1Frontiers in Pharmacology. Variation in adverse drug events of opioids in the United States In practical terms, a doctor who switches a patient from 10 mg of hydrocodone to oxycodone would prescribe somewhere around 6.5 to 7.5 mg of oxycodone to deliver the same level of pain control.
This potency difference exists because of how each drug interacts with opioid receptors. Hydrocodone itself has relatively weak binding to the mu-opioid receptor, the main target for pain relief. Its binding affinity is about 19.8 nanomolar, which is modest. Much of hydrocodone’s clinical punch comes from its metabolite, hydromorphone, which binds the mu receptor far more tightly at 0.6 nanomolar.2PubMed. Mu receptor binding of some commonly used opioids and their metabolites Oxycodone follows a similar pattern: it has a methoxy group at position 3 that weakens its own receptor binding, but its metabolite oxymorphone is a potent mu agonist. The key difference is that oxycodone appears to achieve slightly more analgesic effect per milligram even before metabolism, giving it the edge in raw potency.
Head-to-Head in Acute Pain
If oxycodone is 50 percent stronger per milligram, you might expect it to crush hydrocodone in head-to-head trials. It doesn’t. When both drugs are dosed at equivalent strengths, clinical studies consistently find that they produce nearly identical pain relief.
One double-blind trial gave emergency department patients with fractures either oxycodone or hydrocodone (both combined with acetaminophen) and tracked pain scores over an hour. Both groups improved, and the difference between the two drugs was not statistically significant at either 30 or 60 minutes.3PubMed. Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial A separate trial of adults discharged from the emergency department with musculoskeletal pain compared 5 mg oxycodone/acetaminophen to 5 mg hydrocodone/acetaminophen. Over two hours, both groups saw pain scores drop by about half. The difference between the groups was less than half a point on a ten-point scale, which was neither clinically nor statistically meaningful.4PubMed. Comparative Analgesic Efficacy of Oxycodone/Acetaminophen Versus Hydrocodone/Acetaminophen for Short-term Pain Management in Adults Following ED Discharge
These findings make sense once you understand that the doses given in these trials were already adjusted for potency. A 5 mg oxycodone tablet and a 5 mg hydrocodone tablet are not equivalent doses; the oxycodone tablet is effectively the stronger one, even though the number on the label is the same. That built-in potency advantage is precisely why the two drugs look so similar in pain relief: prescribers and researchers already factor in the difference before anyone swallows a pill.
After Surgery and in Longer-Term Use
One area where the two drugs diverge, at least in some data, is postoperative pain. A large study of patients undergoing hip or knee replacement found that those given hydrocodone actually reported slightly lower pain scores than those given oxycodone. The hydrocodone group also used considerably less total opioid, measured in morphine equivalents.5JAMA Network Open. Hydrocodone vs Oxycodone and Postoperative Pain and Opioid Use in Joint Arthroplasty That result ran counter to the researchers’ own hypothesis, and while the pain-score difference was small in absolute terms, the gap in total opioid consumption was not. One possible explanation is that hydrocodone’s side-effect profile allowed patients to tolerate it better, so they needed less supplemental medication.
For chronic pain, the picture is murkier because the two drugs are rarely compared directly over long periods. One study followed patients with chronic pain who were switched from immediate-release oxycodone to extended-release hydrocodone. Pain severity scores dropped during the switch and stayed lower through the maintenance period, and patients reported less interference with daily activities as well.6Pain Medicine. Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain That isn’t quite an apples-to-apples comparison, because the switch also changed from an immediate-release to an extended-release formulation, which itself smooths out pain control. Still, it suggests that hydrocodone holds its own even against the supposedly stronger drug.
Why Your Genetics Might Not Matter as Much as You Think
Both hydrocodone and oxycodone are metabolized in part by a liver enzyme called CYP2D6, which converts them into their more potent metabolites. People carry different versions of the gene for this enzyme. Some are ultrarapid metabolizers who convert the drug quickly, others are poor metabolizers who barely convert it at all. In theory, a poor metabolizer taking hydrocodone should get less pain relief, because less of it gets turned into the more potent hydromorphone.
Clinical pharmacogenetics guidelines acknowledge that CYP2D6 plays a role in metabolizing both drugs, but describe the evidence linking CYP2D6 status to actual clinical outcomes for hydrocodone and oxycodone as limited and weak.7PubMed Central. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy That stands in contrast to codeine and tramadol, where CYP2D6 status clearly matters and guides prescribing recommendations. A recent study of surgical patients tested this directly: among people taking hydrocodone, CYP2D6 poor metabolizers used about the same amount of drug and reported similar pain intensity as normal metabolizers. The same held true for oxycodone users.8Frontiers in Pharmacology. CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodone
The take-home here is that if you’ve had genetic testing showing you’re a CYP2D6 poor metabolizer, that’s a bigger deal for codeine and tramadol than for hydrocodone or oxycodone. For these two drugs, the parent compound itself contributes enough analgesic activity that the metabolite isn’t the whole story.
Side Effects and How They Feel
Both hydrocodone and oxycodone produce the classic opioid side-effect profile: nausea, constipation, drowsiness, itching, and some degree of respiratory depression at higher doses. A laboratory study that gave both drugs to experienced opioid users found that all the standard mu-opioid effects showed up in dose-related fashion for both drugs, including constricted pupils and modest respiratory depression.9Drug and Alcohol Dependence. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers
Where they diverge somewhat is in subjective effects. At the same 10 mg dose, oxycodone produced a broader range of statistically significant subjective effects than hydrocodone, including greater feelings of “liking” and “high.”10PubMed. Subjective, psychomotor, and physiological effects profile of hydrocodone/acetaminophen and oxycodone/acetaminophen combination products Keep in mind that a 10 mg dose of oxycodone is a stronger dose than 10 mg of hydrocodone based on the potency conversion discussed above, so some of that broader subjective effect is simply a consequence of the higher effective dose. But this difference in “how it feels” has implications for abuse potential, which is worth understanding separately.
Overdose Risk and Abuse Liability
A large retrospective study tracking over half a million patients who received their first opioid prescription found that those initially prescribed oxycodone had a 65 percent higher risk of overdose compared to those started on hydrocodone. When the researchers drilled into formulation type, oxycodone prescribed alone (without acetaminophen) roughly doubled the overdose risk. Even oxycodone combined with acetaminophen carried a 26 percent increase.11PLOS ONE. Opioid-related overdose and chronic use following an initial prescription of hydrocodone versus oxycodone Interestingly, in the same study, patients who started on oxycodone were slightly less likely to develop chronic opioid use than those started on hydrocodone, though the difference was small.
Why would oxycodone carry higher overdose risk? Part of the answer is straightforward: it’s a more potent drug, so accidentally or intentionally taking too much produces a stronger effect. Part of it may relate to those broader subjective effects, which could encourage dose escalation. And part of it may be a formulation issue. Hydrocodone was for decades available only in combination with acetaminophen or ibuprofen, which put a ceiling on how much someone could take before liver or stomach damage became the limiting factor. Oxycodone has long been available as a single-ingredient product in both immediate-release and extended-release forms, removing that built-in guardrail.
How Scheduling Changed the Landscape
Until October 2014, hydrocodone combination products were classified as Schedule III controlled substances in the United States, while oxycodone was Schedule II. Schedule II drugs face stricter prescribing rules: no refills, no phone-in prescriptions, mandatory in-person visits. In 2014, the DEA reclassified hydrocodone combinations to Schedule II as well, putting the two drugs on equal regulatory footing.
The effects were dramatic. A systematic review found that hydrocodone prescribing dropped by anywhere from 3 to 66 percent across different studies after the rescheduling. But the drugs people weren’t getting as hydrocodone didn’t just disappear from the system. Prescribing of oxycodone-containing products increased by roughly 5 to 14 percent, tramadol prescribing rose by 3 to 53 percent, and codeine prescriptions climbed as well.12PubMed. Effects of hydrocodone rescheduling on opioid use outcomes: A systematic review An Ohio-specific study confirmed a similar pattern: oxycodone prescriptions had already been rising before the schedule change and continued to do so afterward.13Pain Medicine. Effects of Rescheduling Hydrocodone on Opioid Prescribing in Ohio
The unintended substitution effect matters for the strength question because many patients who might previously have been prescribed hydrocodone ended up on oxycodone or tramadol instead. Whether that shift helped or hurt public health is still debated. Given the overdose data above, pushing patients toward oxycodone as a substitute could carry real risks.
Abuse-Deterrent Formulations
One area where oxycodone has received more pharmaceutical engineering attention is in abuse-deterrent technology. Extended-release oxycodone products like OxyContin now use technology that makes the tablet hard to crush and turns gummy in water, discouraging people from snorting or injecting it. Another extended-release oxycodone product, Xtampza ER, uses a different approach that retains its extended-release characteristics even when chewed or crushed, making it the only extended-release opioid without a boxed warning against those types of manipulation.14PubMed Central. Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access Extended-release hydrocodone products exist too, but the abuse-deterrent space has been more heavily developed around oxycodone formulations, likely because oxycodone’s higher potency and broader subjective effects make it a bigger target for misuse.
These formulations don’t make the drugs “safe” from abuse. They raise the barrier to non-oral routes of administration, but someone who swallows the pills as intended can still take too many. And abuse-deterrent features add cost, which matters when you look at who’s paying.
Cost and Prescribing Volume
Hydrocodone has historically been prescribed far more often than oxycodone. Over a 29-year period in U.S. Medicaid programs, hydrocodone accounted for roughly 247 million prescriptions as a single-ingredient opioid, compared to about 112 million for oxycodone. Yet spending told a different story: total opioid spending in that population was about $19.4 billion, with oxycodone accounting for approximately $7.3 billion of it and hydrocodone only about $3.3 billion.15PubMed Central. Utilization, Spending, and Price of Opioid Medications in the US Medicaid Programs Between 1991 and 2019 Oxycodone was prescribed roughly half as often but cost more than twice as much in total. That disparity reflects a combination of higher per-unit pricing, more frequent use of branded extended-release formulations, and the abuse-deterrent technologies baked into certain oxycodone products.
For a patient paying out of pocket or managing a high copay, the cost difference can influence which drug a prescriber selects, especially when the clinical evidence shows the two drugs work about equally well for most pain situations.
An Animal Finding Worth Knowing About
Most comparisons between these two drugs focus on human pain trials, but one animal study produced a result that adds a wrinkle. Researchers studying burn-injury pain in rats found that hydrocodone was more effective than either morphine or oxycodone at suppressing the development of mechanical allodynia, a heightened sensitivity to touch that can follow tissue injury. Additionally, morphine produced significant opioid-induced hyperalgesia (a paradoxical increase in pain sensitivity from the opioid itself), while hydrocodone produced only minimal hyperalgesia and oxycodone produced none.16Pain Medicine. Hydrocodone is More Effective than Morphine or Oxycodone in Suppressing the Development of Burn-Induced Mechanical Allodynia
This is a single animal study, and translating findings from rats to humans is always uncertain. But the result is intriguing because opioid-induced hyperalgesia is a real clinical concern in people on long-term opioid therapy. If hydrocodone genuinely carries a lower risk of triggering this paradoxical pain sensitivity, that could matter for patients being treated over weeks or months. It’s an area that needs more human research, but it hints that the “weaker” drug might have some advantages that don’t show up in simple potency comparisons.
When the Acetaminophen Matters
For years, hydrocodone was available in the U.S. only as a combination product paired with acetaminophen (Vicodin, Norco) or ibuprofen. That pairing added a non-opioid pain reliever, which often improves overall pain control while allowing a lower opioid dose. But it also introduced the risk of acetaminophen toxicity. Taking more hydrocodone to chase better pain relief meant taking more acetaminophen too, and exceeding about 3 to 4 grams of acetaminophen per day can cause serious liver damage, especially in people who drink alcohol or have existing liver problems.
Oxycodone has long been available both in combination with acetaminophen (Percocet) and as a standalone drug (OxyContin, Roxicodone). The availability of oxycodone without acetaminophen means there’s no built-in ceiling from liver-toxicity concerns, which is both an advantage for patients who genuinely need higher opioid doses and a risk factor for overdose, as the data above suggests. Since 2014, single-entity extended-release hydrocodone (Hysingla, Zohydro) has also been on the market, removing the acetaminophen constraint for hydrocodone as well. But the combination formulations remain by far the most commonly prescribed versions of both drugs.
If you have liver disease or drink regularly, the acetaminophen component deserves a conversation with your prescriber regardless of which opioid you’re taking. And if you’re taking any other over-the-counter products that contain acetaminophen, like cold medicines or sleep aids, the combined dose can sneak up on you.